^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ALK mutation

    i
    Other names: NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
    Entrez ID:
    238
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    4d
    STAR-121: Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=1069, Recruiting, Gilead Sciences | Trial completion date: Jun 2028 --> Jan 2029
    Trial completion date • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF mutation • ALK mutation • RET mutation
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • Yutuo (zimberelimab) • domvanalimab (AB154)
    5d
    Dysregulation of Extracellular Matrix Genes Identifies Neuroblastoma Patients at High Risk of Recurrence and Poor Outcome. (PubMed, J Pediatr Hematol Oncol)
    ECM gene signatures serve as robust prognostic markers across populations. This function-based approach offers a novel perspective to address genetic heterogeneity and provides a theoretical foundation for ECM-targeted combination therapies.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    ALK mutation
    7d
    A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers (clinicaltrials.gov)
    P1/2, N=73, Terminated, Ocellaris Pharma, Inc. | Trial completion date: Sep 2026 --> Nov 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2026 --> Nov 2025; Business Decision
    Trial completion date • Trial termination • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • PGR (Progesterone receptor) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    HER-2 negative • ALK fusion • ALK mutation • ROS1 fusion
    |
    Bavencio (avelumab) • OC-001
    8d
    Differential Prevalence and Prognostic Significance of Spread Through Air Spaces According to Oncogenic Driver Mutations in Lung Adenocarcinoma. (PubMed, J Thorac Cardiovasc Surg)
    The prevalence and prognostic significance of STAS varied by driver mutation status, suggesting that the clinical interpretation of STAS may depend on the molecular context.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    KRAS mutation • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • ALK rearrangement • EGFR wild-type • ALK mutation • ROS1 rearrangement
    10d
    TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy (clinicaltrials.gov)
    P2, N=41, Recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial • Checkpoint inhibition
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • IL2 (Interleukin 2)
    |
    ALK mutation • EGFR negative
    |
    Tevimbra (tislelizumab-jsgr)
    13d
    Screening With Whole Body MRI For Detection Of Primary Tumors In Children And Adults With Li-Fraumeni Syndrome (LFS) And Other Cancer Predisposition Syndromes (clinicaltrials.gov)
    P=N/A, N=150, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • VHL (von Hippel-Lindau tumor suppressor)
    |
    TP53 mutation • ALK mutation • VHL mutation
    14d
    Malignant melanoma with anaplastic lymphoma kinase positivity: a clinicopathological analysis of three cases (PubMed, Zhonghua Bing Li Xue Za Zhi)
    Aberrant ALK activation suggests its potential role in molecular pathogenesis of malignant melanoma. Further investigation of ALK as a therapeutic target seems necessary.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS mutation • BRAF mutation • NRAS mutation • PIK3CA mutation • ALK positive • ALK rearrangement • ALK fusion • ALK mutation
    18d
    Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative (clinicaltrials.gov)
    P2/3, N=427, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • ALK mutation
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • paclitaxel • ABP 206 (nivolumab biosimilar)
    18d
    A case report of neoadjuvant targeted therapy in stage IIIA non-small cell lung cancer with BRAF V600E mutation. (PubMed, Front Med (Lausanne))
    The postoperative pathology review revealed a pathological complete response (pCR). This case illustrates that BRAF and mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor therapy may represent a viable option for neoadjuvant therapy in locally advanced BRAF V600E mutant NSCLC.
    Journal • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase)
    |
    BRAF V600E • BRAF V600 • ALK mutation
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib)
    18d
    Weight, BSA, Toxicity, and Efficacy of Tyrosine Kinase Inhibitors for ALK-Mutated NSCLC. (PubMed, JTO Clin Res Rep)
    In contrast, permanent discontinuation was associated with higher weight/BSA in brigatinib/ceritinib/crizotinib-treated patients. Higher weight and larger BSA at the start of ALK TKI treatment were associated with higher likelihood of toxicity, leading to more DRs and TIs-particularly in males and patients receiving alectinib and lorlatinib. However, weight and BSA were not associated with treatment outcomes.
    Journal
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive • ALK mutation
    |
    Xalkori (crizotinib) • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • Alunbrig (brigatinib)
    19d
    Assessment of Circulating Tumor DNA for Early Detection of Hepatocellular Carcinoma in Alpha-Fetoprotein-Negative Patients With Cirrhotic Nodules. (PubMed, JGH Open)
    Over a five-year follow-up period, 50% of ctDNA-positive patients were diagnosed with early-stage HCC, with a mean lead time of 26.6 months compared to standard clinical assessments. By enabling diagnosis months earlier than conventional methods, ctDNA-based testing may enhance HCC surveillance and facilitate a more personalized approach to cancer monitoring.
    Journal • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • ALK (Anaplastic lymphoma kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • FGFR3 (Fibroblast growth factor receptor 3) • NF1 (Neurofibromin 1) • AFP (Alpha-fetoprotein)
    |
    HER-2 mutation • FGFR3 mutation • ALK mutation
    20d
    Safety and Efficacy of Alectinib in the First Line for ALK-Mutated Lung Cancer: A Real-World Data from India. (PubMed, South Asian J Cancer)
    No drug interruption or dose modifications were needed in any patient. This real-world data from LMIC confirm the safety and efficacy of alectinib in the first-line setting matching that of registration studies with similar safety and tolerance, without any new alarm.
    Journal • Real-world evidence
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive • ALK mutation
    |
    Alecensa (alectinib)